BioRestorative Therapies, Inc.
About BioRestorative Therapies, Inc.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $359.7K
- Net income
- -$14.2M
- Total assets
- $4.1M
- Market cap
- $10.3M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $10.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 22, 1997
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review BioRestorative Therapies, Inc..